Skip to main content
SpringerLink
Log in

Indacaterol/glycopyrronium cost effective for COPD

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2015 euros

Reference

  • Maleki-Yazdi MR, et al. Cost Effectiveness of the Long-Acting beta2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal. Applied Health Economics and Health Policy : 11 Aug 2016. Available from: URL: http://dx.doi.org/10.1007/s40258-016-0256-z

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Indacaterol/glycopyrronium cost effective for COPD. PharmacoEcon Outcomes News 760, 22 (2016). https://doi.org/10.1007/s40274-016-3323-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3323-7

Search

Navigation